Register or Sign in to Save this opportunity, or Send an Inquiry.
New Chemical Entities and Innovative Therapeutic Targets
Zambon SpA Italy flag Italy
Abstract ID:
NCEs for innovative therapeutic targets in inflammatory/immunologic diseases.
Send an Inquiry
Zambon's R&D core competences range from hit-to-lead optimization up to full drug development. Its Lead Optimization Unit is capable to quickly bridge the gap between hit discovery and pre-clinical development and to reduce the risk of failures in clinical development. Zambon's R&D wants to become a valuable partner for all those Drug Discovery companies that want to add value to their lead molecules and see their candidate drugs enter riskless into development.
Type of Business Relationship Sought
Companies having proprietary hits/lead compounds for innovative targets or proprietary targets and screening capabilities, will find a dynamic group capable to either optimize existing compounds or discover new hits. Zambon business model is based on collaboration aiming at bringing values to all partners. Roles and responsibilities can be flexibly arranged to obtain a successful and well-balanced relationship among partners.
Last Updated Feb 2018
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE

Opportunity Contact

Warning: include(js_message_scripts_n2.php) [function.include]: failed to open stream: No such file or directory in /home/pharmalicensing/public_html/detail.php on line 833

Warning: include() [function.include]: Failed opening 'js_message_scripts_n2.php' for inclusion (include_path='.:/usr/lib/php:/usr/local/lib/php') in /home/pharmalicensing/public_html/detail.php on line 833